GlassScriptPhysician profile
Theodore Geffen
NPI 1073511861
$2,655.54
in general payments reported to CMS, 2019-2025
40 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $316 · 2021: $284 · 2022: $193 · 2023: $391 · 2024: $159 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $369.52 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Abbvie INC. | $312.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $248.40 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $242.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $215.36 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $133.13 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $118.68 | 2019-2024 | |
| Boston Scientific Corporation | $70.45 | 2019-2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.43 | 2019-2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $62.72 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $58.77 | 2019 | |
| Emd Serono, INC. | $56.32 | 2019-2020 | |
| Dexcom, INC. | $48.13 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $45.73 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $45.24 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Geffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.